Portfolio
Viriom Inc.
Viriom Inc., a San Diego CA-based biotech, is advancing breakthrough medicines that are effective and affordable with the ultimate goal of curing HIV, chronic HBV and respiratory infections in both developing and developed countries. Viriom's pipeline includes: Elpida® (elsulfavirine), the best-in-class NNRTI that obtained first market authorization in 2017; extended release weekly oral formulations; and long-acting injectable therapy and prophylaxis. Viriom combines its extended release and long-acting injectable compounds with partners’ therapies with curative potential.
Afraxis Inc.
Afraxis Inc. is a contract research organization (CRO) specializing in:
CNS preclinical efficacy evaluations (in vivo & in vitro)
Neurotoxicity evaluations
Structure-Efficacy Relationship (SER)-driven medicinal chemistry
Afraxis' patented ESP (Enhanced Spine Profiling) technology produces rapid, high-information read-outs of synaptic networks from in-vivo/in-vitro/ex-vivo preparations. The ESP process incorporates specialized labeling of individual neurons; high-resolution imaging; rapid high-detail morphometry of individual cells, processes, and synapses; and powerful statistical methods and analytical displays tailored for efficient interpretation of large data sets.
i2020 Accelerator
By rapidly de-risking novel science and enriching partner pipelines with best-in-class molecules, i2020 helps accelerate early stage drug discovery platforms towards advanced lead and clinical candidate level within a two-year time framework. i2020's vast scientific and global resource network tailored specifically to the needs of early drug development programs allows it to take on projects in a wide array of therapeutic areas, from immunology to infectious diseases and beyond.
Chromis Therapeutics
Chromis Therapeutics, Inc. (Chromis) is a San Diego-based biopharmaceutical company, focused on the development of curative treatments for chronic HBV (Hepatitis B virus) infection, based on its advanced proprietary drug design and discovery platform. The company is developing its novel cccDNA (covalently closed circular DNA), viral entry and viral capsid assembly inhibitor lead candidates for the treatment of chronic HBV. Novel proprietary small molecule combinations have the potential to eradicate HBV and to efficiently cure chronically infected HBV patients, as compared to drugs currently on the market.
Avelas Biosciences
Avelas Biosciences is a clinical-stage drug-device company focused on developing and commercializing pegloprastide (also known as AVB-620) with the goal of revolutionizing cancer surgery with real-time margin detection. In a prospective trial in women with early-stage breast cancer undergoing a lumpectomy, intraoperative imaging of pegloprastide detected up to 75% of the positive margins that resulted from standard-of-care techniques. Beyond breast cancer, pegloprastide has the potential to significantly improve outcomes in a variety of other cancer surgeries.
Leap Therapeutics
Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
Vaxxas
Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary HD-MAP technology platform, which uses an ultra-high density array of projections – invisible to the naked human eye – applied to the skin to rapidly deliver vaccine to the abundant immune cells immediately below the skin surface. This approach can enhance efficiency and effectiveness of immune response. Vaxxas uses proprietary dry-coating technology that can eliminate or significantly reduce the need for vaccine refrigeration during storage and transportation – easing the resource and logistics burden of maintaining the “cold chain.” Vaxxas is targeting initial applications in infectious disease and oncology.
Context Therapeutics
Context Therapeutics Inc., is a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers. The Company’s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian, and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel, first-in-class small molecule under development as a potent and specific antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women’s cancers. Context is headquartered in Philadelphia, PA.
Polku Therapeutics
Polku Therapeutics Oy is carving a new path to a healthy aging brain by developing novel disease-modifying therapies for neurodegenerative disorders. Currently, we are advancing our proprietary compounds through key development milestones to offer new treatment options for conditions like Parkinson’s disease, Alzheimer's disease, and frontotemporal dementia.